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ABSTRACT

Familial hypercholesterolemia (FH) is a genetic condition characterized by elevated
levels of low-density lipoprotein cholesterol (LDL-C) that leads to an increased risk of
developing cardiac disease early in life (Shah et al., 2020). Current treatments such as statins
and PCSK9 inhibitors have helped lower LDL-C levels, however they require repeated
administration every 4-6 weeks to remain effective (Raal et al., 2018).
Angiopoietin-like 3 (ANGPTL3) is an inhibitor of plasma lipid metabolism that has
become a promising molecular target for the treatment of FH. Individuals with non-functional
copies of ANGPTL3 demonstrate low levels of plasma LDL-C and triglycerides, indicating a
protective effect against coronary heart disease (Wang, X. & Musunuru, 2019). ANGPTL3
inhibitors have also shown effective reduction in LDL-C and triglyceride levels.
CRISPR-Cas9 is a gene editing tool that uses a guide RNA (gRNA) to direct the Cas9
nuclease to a target site in the genome to induce a double strand break (DSB) and is widely
used due to its high levels of editing activity and amenability to multiplexing. Gene editing
may be used to treat FH by delivering functional copies of defective genes or knocking down
target genes that are associated with lipoprotein metabolism such as ANGPTL3. The main
challenge associated with ex vivo gene editing for liver-based diseases is selecting for cells
that have been edited. Acetaminophen (APAP) selection is a novel method to overcome this
barrier that combines the delivery of therapeutic transgenes with the knockdown of the
CYPOR gene that produces toxic metabolites to provide a selective advantage to edited cells
(Vonada et al., 2021). These principles can be utilized to form a novel multiplex gene editing
approach that targets ANGPTL3 and CYPOR using CRISPR-Cas9 for the treatment of FH.
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In this project we designed gRNAs targeting Angptl3, evaluated their specificity, and
quantified their editing efficiencies in mouse Hepa 1-6 cells and primary mouse hepatocytes.
Next, we evaluated whether disruption of Angptl3 using CRISPR-Cas9 plasmid DNA lowers
serum levels of Angptl3 and triglycerides in an Ldlr knockout mouse model. Our results
showed high editing efficiency in primary mouse hepatocytes and significant reductions in
triglyceride levels.
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CHAPTER ONE
FAMILIAL HYPERCHOLESTEROLEMIA
1.1 Disease Characteristics and Causes
Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated
levels of low-density lipoprotein cholesterol (LDL-C), leading to an increased risk of
developing cardiovascular disease early in life (Youngblom et al., 2014). FH occurs in around
1 in 250 people and the disease onset typically begins in childhood (Shah et al., 2020).
Symptoms of FH can be seen as increased carotid intimal thickness, coronary artery
calcification, and other manifestations of coronary artery disease (Shah et al., 2020). As the
disease progresses and cholesterol levels remain high, cholesterol deposits in the skin of the
eyelids (xanthelasma) or around connective tissue and tendons (xanthoma) can also be seen
(Youngblom et al., 2014). Diagnosis is done by measuring lipid levels, with emphasis on
LDL-C, identifying family history of FH or premature cardiac disease, and looking for
physical signs including xanthelasma or xanthoma (Shah et al., 2020). Genetic testing can
also look for any pathogenic variants in genes that are associated with FH (Youngblom et al.,
2014).
FH is inherited in an autosomal dominant manner and affected individuals may be
homozygous or heterozygous for mutations. Homozygous FH occurs in around 1 in 300,000
people and affected individuals have more severe symptoms compared to individuals with the
heterozygous form (Youngblom et al., 2014). Pathogenic variants in three main genes, shown
in Figure 1.1, have been identified as causes of FH. Over 75% of cases are caused by
mutations in the LDL receptor gene (LDLR), resulting in defective LDL receptors that are
unable to take up LDL-C from circulation (Shah et al., 2020). FH may also be caused by
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mutations that cause dysfunction in the apolipoprotein B (APOB) gene, resulting in reduced
binding of LDL-C to LDL receptors (Shah et al., 2020). Gain-of-function mutations in the
gene proprotein convertase subtilisin kexin type 9 (PCSK9) are also a cause of FH due to
increased activity of PCSK9 that degrades LDL receptors (Shah et al., 2020).

Figure 1.1: Genetic mutations that cause FH.
1.2 Current Treatments
1.2.1 Statins
Statins are the primary pharmacological treatment for individuals with FH to lower LDLC. Statins act by inhibiting hydroxymethylglutaryl-CoA (HMG-CoA) reductase, an enzyme
that plays a role in the synthesis of cholesterol (Ratchford & Smith, 2017). Inhibiting HMGCoA results in an upregulation of LDL receptors by the liver that remove LDL-C from
circulation (Ratchford & Smith, 2017). Children with FH typically begin lower doses of statin
therapy immediately after diagnosis, combined with lifestyle modifications such as low-fat
diet and increased exercise (Raal et al., 2018). Adults with FH are usually treated with the
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highest dose of statin therapy that can be tolerated, but statin therapy alone is typically
inadequate in reducing LDL-C to the recommended levels (Raal et al., 2018).
1.2.2 PCSK9 Inhibitors
PCSK9 is a protein that degrades LDL receptors on the surface of liver cells, inhibiting
the removal of cholesterol from the bloodstream (Raal et al., 2018). Alirocumab and
evolocumab are FDA-approved human monoclonal antibodies that bind and inactivate
PCSK9, and individuals that received treatment with these inhibitors, combined with statin
therapy, showed a 39-62% reduction in LDL-C (Everett et al., 2015). While these drugs have
been shown to effectively lower LDL-C, they require administration every 2-4 weeks (Raal et
al., 2020). There are also safety concerns associated with these inhibitors due to the elevation
of liver enzymes that is associated with their use as well as gastrointestinal side effects (Ling
et al., 2021).
1.2.3 Nucleic Acid Therapeutics
Nucleic acids have also been used to lower lipid levels for the treatment of FH. Inclisiran
is a small interfering RNA (siRNA) that inhibits the production of PCSK9 and was approved
by the FDA in 2021. Two doses of inclisiran per year lowered LDL-C levels by up to 52% in
individuals on maximally tolerated statin therapy (Raal et al., 2020). The antisense
oligonucleotide mipomersen targets and degrades apoB mRNA to reduce LDL-C levels (Raal
et al., 2020). This treatment has been promising for individuals with homozygous FH since it
does not rely on the expression of LDL receptors to lower LDL-C levels, and a 24.7%
reduction in LDL-C was reported in patients that received weekly doses of mipomersen
(Jiang, L. et al., 2018). In vivo genome editing with adeno-associated viruses (AAVs) for the
treatment of FH has also advanced to clinical trials. Regenxbio completed phase I/II trials that
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delivered functional copies of LDLR into individuals with homozygous FH after promising
results from preclinical animal models (NCT02651675); however, several patients
experienced positive T cell responses to the AAV as well as elevated levels of transaminases,
and no other efficacy data has been published (Wang, L. et al., 2021)
1.2.4 Non-pharmacological Treatments
Some FH patients may be intolerant or irresponsive to statins or other cholesterollowering medications. Lipoprotein apheresis removes lipoproteins from the blood and is
typically only used for patients with severe or homozygous forms of FH (Raal et al., 2020).
Cholesterol levels also quickly rebound after lipoprotein apheresis, limiting its long-term
efficacy. Liver transplantation is only used for patients with severe homozygous FH that do
not respond to any other treatment but is limited by organ shortages, requirement of lifelong
immunosuppression, and mortality rates (Raal et al., 2020).
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CHAPTER TWO
CRISPR-CAS9

2.1 CRISPR Biology
CRISPR-Cas systems were first identified in the bacterial adaptive immune system to
fight off invading phages and plasmids. The CRISPR system is a segment of DNA that
contains an array of clustered regularly interspaced short palindromic repeats (CRISPR) and
CRISPR-associated (Cas) proteins that are encoded by a cas operon (Hille & Charpentier,
2016). The CRISPR array is made up of alternating repetitive sequences, called repeats, and
non-repetitive sequences called spacers (Hille & Charpentier, 2016) . When phage infection
occurs, fragments of the invasive DNA are integrated into the CRISPR array as new spacers
that will act as a memory of infection in the host DNA (Jiang, F. & Doudna, 2015). The
CRISPR array is transcribed into precursor CRISPR RNAs (pre-crRNAs) then processed into
mature CRISPR RNAs (crRNAs) by Cas enzymes. These crRNAs contain spacers that are
complementary to specific segments of foreign nucleic acids called protospacers. Upon
reinfection by the same invader, the spacers in crRNAs are used as guides for effector
complexes to recognize and target protospacers (Hille & Charpentier, 2016). The protospacer
adjacent motif (PAM), a short sequence downstream of the target site, is also required for
recognition by the effector complex (Jiang & Doudna, 2015). After recognition and binding of
the spacer and protospacer, Cas nucleases cleave the targeted foreign sequence to silence it.
2.2 CRISPR-Cas9 for Gene Editing
The ability of CRISPR-Cas systems to target and destroy specific sequences of DNA
using RNA guidance has been harnessed as a technology to perform genome editing for a
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wide range of applications. There are two main classes of CRISPR-Cas systems that differ in
the number of proteins that are used to form the effector complex for DNA interference (Hille
& Charpentier, 2016). Within the second class, the CRISPR-Cas9 system has been the most
widely studied and used since it shows high levels of editing activity and is amenable to
multiplexing. This system uses a single Cas9 nuclease that recognizes an NGG PAM
sequence on the strand that is complementary to the target sequence (Hille & Charpentier,
2016). In bacteria, CRISPR-Cas9 systems require a two-part guide RNA consisting of a transactivating crRNA (tracrRNA) bonded to the protospacer-targeting crRNA (Hille &
Charpentier, 2016). These two components can be combined into a single guide RNA
(sgRNA) that effectively guides Cas9 to the target site to cleave double stranded DNA (Jiang
& Doudna, 2015). The CRISPR-Cas9 complex can be seen below in Figure 2.2.1.

Figure 2.2.1: CRISPR-Cas9 gene editing complex (Walter, 2017).
Once a break is induced in DNA, there are two natural DNA repair pathways that can
be used to make genomic edits. Non-homologous end joining (NHEJ) is the primary pathway
used by cells that directly ligates the broken ends of DNA together. NHEJ does not require a
DNA template for repair, which makes it largely error prone and usually leads to insertions or
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deletions (indels) in DNA that cause frameshift mutations (Hille & Charpentier, 2016). The
homology-directed repair (HDR) pathway is a precise repair mechanism that requires a
template of DNA to repair DSBs through homologous recombination (Xue & Greene, 2021).
The NHEJ pathway can be used to knock out genes of interest or restore gene expression with
CRISPR-Cas systems while the HDR pathway allows precise sequences of DNA to be
inserted to correct genes and restore function (Hille & Charpentier, 2016).

Figure 2.2.2: DNA repair pathways used to make genomic edits (Walters, 2017).
2.3 Delivery Systems
2.3.1 Viral and Nonviral Vectors
Viral and nonviral delivery systems may be used to deliver gene editing components, with
both systems having distinct advantages and disadvantages. Adeno-associated viruses (AAVs)
are the most widely used viral vector for gene editing used because they have a better safety
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profile compared to other viral vectors. The main limitations with AAVs are their small
carrying capacity for gene editing components. The main advantage of viral vectors is their
high delivery and editing efficiencies. Despite this, a significant portion of the population has
preexisting immunity to viral vectors that limits their safety and efficacy (Glass et al., 2018).
Nonviral delivery systems include physical methods such as electroporation, which
applies a quick voltage to cells, allowing the membrane to be permeable to gene editing
components. Encapsulation of gene editing components using liposomes, lipid nanoparticles
(LNPs) or polymeric nanoparticles help protect nucleic acids from uptake by immunological
cells and can be targeted to certain tissues by the addition of targeting moieties (Glass et al.,
2018). Hydrodynamic injection is a commonly used method that rapidly delivers gene editing
components as naked DNA into small animal models. The injection volume is around 10% of
the animal weight and the high pressure during injection creates temporary permeabilization
of the cell membrane to allow gene editing components in (Ates et al., 2020). This method has
demonstrated effective gene transfer to the liver for several liver-based diseases and has lower
levels of DNA degradation compared to conventional intravenous injection (Huang et al.,
2017). Pankowicz et al. delivered a CRISPR design targeting the Hpd gene into mice for the
treatment of hereditary tyrosinemia and showed an editing efficiency of over 60% in
hepatocytes (2016).
2.3.2 Cas9 Cargo Systems
For effective gene editing to occur, the gRNA and Cas9 must become a functional
complex in the nucleus (Glass et al., 2018). The Cas9 cargo can be delivered in several ways.
Plasmid DNA that codes for the gRNA sequence and Cas9 can be delivered, requiring
transcription of the gRNA and transcription and translation of Cas9 for gene editing to occur.
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Plasmid DNA leads to the stable expression of Cas9, prolonging the time for gene editing to
occur, but can also lead to unwanted off-target editing and cytotoxicity (Glass et al., 2018).
Cas9 can also be delivered as mRNA that must only be translated for editing to occur.
However, mRNA is typically degraded rapidly, leading to transient expression of gene editing
components, which also helps reduce off-target editing (Li et al., 2018). Cas9 may be
delivered as a ribonucleoprotein (RNP) that is complexed with gRNA, avoiding the need for
transcription and translation to occur. This leads to rapid gene editing, but expression is also
transient and the large size of the Cas9 protein makes delivery into the cell and nucleus
difficult (Glass et al., 2018).
2.3.3. In Vivo and Ex Vivo Gene Editing
Gene editing can be done in vivo or ex vivo. In vivo gene editing infuses viral vectors or
lipid nanoparticles that contain the CRISPR-Cas9 components into the patient, either locally
or systemically, where gene editing occurs inside of the body (Hirakawa et al., 2020). In vivo
editing with AAVs has shown success in the treatment of retinal dystrophy and Leber
congenital amaurosis and has the advantage of stable transgene expression (Hirakawa et al.,
2020). Concerns with this method include innate and adaptive immunological responses
induced by AAVs, as well as their potential to integrate into the host genome (Hirakawa et al.,
2020). Ex vivo gene editing removes cells from the patient, performs gene editing outside of
the body, and transplants the edited cells back into the patient (Hirakawa et al., 2020). CAR T
cell therapy has been one of the most successful forms of ex vivo gene therapy. For liverbased applications, the primary limitation of ex vivo gene editing is obtaining high levels of
engraftment of edited cells after they are transplanted back into the patient. Edited cells often
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need a selective advantage to repopulate the target tissue, which is essential to achieve
therapeutic benefits (Ates et al., 2020).
2.4 Acetaminophen Selection
Acetaminophen (APAP) selection is a method that can provide a selective advantage
to edited hepatocytes for genetic disorders associated with the liver. APAP, commonly known
as Tylenol, is metabolized into the toxic compound N-acetyl-p-benzoquinone imine (NAPQI)
by the enzyme NADPH-cytochrome P450 oxidoreductase. Hepatocytes can be edited to
knockdown the CYPOR gene that produces this enzyme, and subsequent APAP
administration will allow only the edited cells to survive and proliferate (Vonada et al., 2021).
Vonada et al. delivered plasmid DNA encoding a Cypor-targeting gRNA and Cas9 into
mouse hepatocytes via hydrodynamic tail vain injection and demonstrated a 35% expansion
of edited cells after APAP administration. Therapeutic transgenes can be linked in cis with the
Cypor-targeting CRISPR, followed by APAP administration, to facilitate the selection and
expansion of edited hepatocytes (Vonada et al., 2021). Cypor-deficient hepatocytes were
present for up to 42 weeks after editing, indicating the long-term stability of this method.
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CHAPTER THREE
ANGIOPOIETIN-LIKE 3
3.1 Role in Lipid Metabolism
Angiopoietin-like 3 (ANGPTL3) is a protein secreted from the liver that regulates
plasma lipid metabolism. ANGPTL3 primarily inhibits the hydrolysis of triglycerides and the
metabolism of HDL-C and plays a less understood role in the regulation of LDL-C levels
(Wang & Musunuru, 2019). Results from one study that silenced Angptl3 expression with
siRNA found that it may regulate LDL-C through reduction of apolipoprotein B (apoB)
secretion and increasing uptake of LDL-C by the liver (Xu et al., 2018). Genome-wide
association studies revealed that individuals with naturally occurring non-functional copies of
the ANGPTL3 gene have lower levels of plasma LDL-C, HDL-C, and triglycerides (Ruhanen
et al., 2020). Individuals carrying mutations in the gene also had a 34% lower risk of
developing cardiovascular disease compared to individuals with functional copies of
ANGPTL3 (Wang & Musunuru, 2019). These factors have led researchers to evaluate
ANGPTL3 as a therapeutic target for the treatment of disorders involving hyperlipidemia and
coronary heart disease.
3.2 ANGPTL3-Based Treatments
Evinacumab is a human monoclonal antibody that targets ANGPTL3. It demonstrated a
reduction in LDL-C levels by up to 59% in patients with homozygous FH, proving the
efficacy of ANGPTL3-targeting therapeutics (Reeskamp et al., 2021). Like PCSK9 inhibitors,
doses are needed every 4 weeks, leading researchers to look at long-term methods of
inhibiting ANGPTL3. The antisense oligonucleotide vupanorsen is being explored in clinical
trials as a treatment for dyslipidemia (NCT04516291); it demonstrated a well-tolerated safety
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profile and a reduction in patient triglyceride and total cholesterol levels by 31% and 19%,
respectively (Ling et al., 2021).
Researchers have also started to use gene editing tools to silence ANGPTL3 expression.
Chadwick et al. delivered base editors targeting Angptl3 into C57BL/6J mice and showed a
reduction in plasma Angptl3, triglyceride, and cholesterol levels by 49%, 31%, and 19%
respectively (2018). In Ldlr knockout mice that model homozygous FH, a 51% reduction in
cholesterol and 56% reduction in triglycerides was observed after delivery of the base editor
(Chadwick et al., 2018). Another recent study by Qiu et al. delivered a CRISPR-Cas9 design
targeting Angptl3 into C57BL/6J mice using LNPs. They demonstrated a 65% knockdown in
serum levels of Angptl3 protein as well as a 56% reduction in LDL-C and 29% reduction in
triglyceride levels (2021). These promising results demonstrate the potential for gene editingmediated knockdown of ANGPTL3 for the treatment of FH.
3.3 Project Overview
In this study, we designed five different gRNAs targeting Angptl3 and evaluated their
specificity using in-silico tools. The Angptl3-targeting CRISPRs were electroporated into
mouse Hepa 1-6 cells and the delivery and editing efficiencies were quantified. We also
evaluated the editing efficiency of our first design, Angptl3-1, in primary mouse hepatocytes
using different forms of Cas9, delivering it as mRNA and RNP. Finally, we delivered the
CRISPR into Ldlr knockout mice to evaluate whether disruption of Angptl3 using CRISPRCas9 plasmid DNA lowers Angptl3 and cholesterol levels. These preliminary results will be
used for future work to develop a novel multiplex ex vivo gene editing approach that involves
targeting ANGPTL3 and CYPOR using CRISPR-Cas9 for the treatment of FH. Our approach
would first isolate hepatocytes from the patient’s resected liver, followed by ex vivo editing to
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knock out ANGPTL3 and CYPOR. The edited cells would be transplanted back into the
patient, followed by transient APAP administration to select for edited cells.
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CHAPTER FOUR
MATERIALS AND METHODS

4.1 Designing Guide RNAs
The Benchling CRISPR Guide RNA Design Tool (benchling.com) was used to design
sgRNAs targeting the Angptl3 gene in the genome GRCm38 (mm10, Mus musculus). The
parameters were set to a 20-nucleotide length with an NGG PAM sequence. Exon 1 was
chosen as the target region (corresponding to the genomic position chr4 99,030,954—
99,031,499) and 40 total sequences were generated, with each sequence having on-target and
off-target scores. The on-target score is an optimized measure of the predicted activity of the
gRNA (Doench et al., 2016). The off-target score is a measure of the number of predicted offtarget sites according to the method of Hsu et al. (2013). Both scores are reported as values
from 0-100 where higher values indicate better scores. The top 5 sequences with the highest
on-target score were selected for use and are shown in Table 5.1.1.
4.2 Estimating Off-Target Sites
COSMID (CRISPR Off-target Sites with Mismatches, Insertions, and Deletions) is an
in-silico tool that identifies and ranks potential off-target sites for gRNAs (Cradick et al.,
2014). Mus musculus GRC38 (mm10) was selected as the target genome and the PAM suffix
was entered as NRG. For the allowed indels and mismatches, the following parameters were
used and can be seen in Figure 4.1: No indels – up to 3 mismatches; 1-base deletion – up to 1
mismatch; 1-base insertion – up to 1 mismatch. All 5 gRNA designs were entered as the query
sequence with the first nucleotide replaced with an N.
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Figure 4.1: COSMID parameters used to identify off-target sites.
The COSMID output represents sites in the genome that perfectly or partially match to
the gRNA sequence query with up to 3 base mismatches or single insertions or deletions.
Sites are given a ranking score where lower scores are more likely to be true off-target sites
(Cradick et al., 2014). Sites were sorted by chromosome position and duplicate sites were
removed, keeping only the site with the lowest score. Next, sites were sorted by score from
lowest to highest. Sites were then ranked by the presence of indels in the PAM site, given the
following priority: NGG mismatches > NRG mismatches > NGG indel + mismatch > NRG
indel + mismatch. The final number of ranked off-target sites were counted for each gRNA
design.
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4.3 Plasmid Preparation
The pX330-U6-Chimeric_BB-CBh-hSpCas9, a gift from Feng Zhang (Addgene
plasmid #42230) was streaked on an LB agar plate then incubated overnight at 37˚C. This
plasmid contains a region to insert a gRNA sequence and encodes Cas9 along with a U6
promoter (Cong et al., 2013). A single bacterial colony from the plate was inoculated into 5
mL LB medium (Fisher Bioreagents) containing 5 μL ampicillin and incubated for 12 hours at
37˚C. The QIAprep Spin Miniprep Kit (Qiagen) was used to isolate plasmid DNA according
to the manufacturer’s directions. Restriction enzymes were used to digest the plasmid by
combining 10 μg of plasmid DNA (8.6 μL) with 5.0 μL 10x rCutSmart (New England
Biolabs), 1.0 μL BbSI (New England Biolabs), and 35.4 μL nuclease free water, followed by
overnight incubation at 37˚C. The digested vector was cleaned up by adding 2 μL alkaline
phosphatase (Quick-CIP, New England Biolabs) and incubating at 37˚C for 1.5 hours
followed by 10 μL of a stop solution. The digested vector was purified using AgenCourt
AMPure XP magnetic beads (Beckman Coulter). The DNA concentration was measured
using a Nanodrop 2000 Spectrophotometer (ThermoFisher). Oligonucleotides that contain the
5 different guide sequences targeting the mouse Angptl3 gene (Eurofins Genomics) were
annealed and ligated into the pX330 plasmid using standard cloning procedures. The ligated
vectors were transformed into MultiShot TOP10 Chemically Competent E. coli
(ThermoFisher) and spread onto LB plates containing ampicillin. One colony was selected
from each plate and grown in 5 mL LB broth containing 5 μL ampicillin overnight at 37˚C
with vigorous shaking. A glycerol stock was made for each design. To confirm that the guide
sequence was correctly inserted, plasmid DNA was isolated from the remainder of the
overnight culture using the QIAprep Spin Miniprep Kit (Qiagen). 5 μL of the miniprep
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product was sent for Sanger sequencing (Eurofins Genomics) with 5 μL of 2 mM U6sponge-F
primer (sequence listed in Table 4.8, from Eurofins Genomics). After confirming that all five
Angptl3-targeting guide sequences were correct, plasmid DNA was isolated according to the
manufacturer’s instructions using a QIAGEN Plasmid Maxi Kit (Qiagen). DNA concentration
and A260/280 values were measured on a Nanodrop.
4.4 Cell Culture
Hepa 1-6 cells (ATCC) were cultured using Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1X antibioticantimycotic. Cultures were maintained in a humidified incubator at 37˚C with 5.0% CO2.
4.5 Electroporation into Hepa 1-6 Cells
A 4D-Nucleofector X Unit (Lonza) was used to electroporate the plasmid DNA
encoding the Angptl3-targeting CRISPR designs into Hepa 1-6 cells. Cells were detached
using 0.25% Trypsin EDTA (Fisher Scientific) and counted using an automated cell counter
with trypan blue. The following conditions were used for each reaction: 20 μL SF Cell 4DNucleofector Solution (Lonza), 1x105 cells, and 1 μg plasmid DNA. To estimate the delivery
efficiency, cells were electroporated with 0.4 μL of 1 μg/μL pmaxGFP (Lonza). Untransfected
cells were used as a negative control and were only resuspended in the nucleofector solution.
Ten minutes after electroporation, cells were transferred into a 96-well plate that was
prewarmed with media. All reactions were done in duplicates with n=3.
4.6 Electroporation into Primary Mouse Hepatocytes
4.6.1 Hepatocyte Isolation
Mouse hepatocytes were isolated from 7-week-old C57BL/6J mice (Charles River
Laboratories) following a protocol from Rathbone et al. (2022). The vena cava was
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cannulated and the liver was perfused with three different digestive solutions. The liver was
excised and dissected to disrupt liver capsules and hepatocytes were washed out and
collected. Hepatocytes were filtered and added to a solution of ice-cold DMEM supplemented
with 10% FBS. Hepatocytes were centrifuged at 50 x g and washed until all supernatant was
removed, followed by resuspension in DMEM containing 10% FBS. Trypan blue was used to
count cells and determine viability.
4.6.2 Electroporation
For electroporation, Cas9 was delivered as an RNP and as mRNA. For both reactions,
30 μg (1.5 μL) of Angptl3-1 sgRNA was used. For reactions that delivered Cas9 as an RNP,
the sgRNA was incubated with 300 pmol (4.7 μL) Alt-R S.p Cas9 Nuclease V3 (Integrated
DNA Technologies) for 10 minutes at room temperature. Reactions that delivered Cas9 as
mRNA used 4 μL CleanCap Cas9 mRNA (TriLink Biotechnologies). To estimate the delivery
efficiency, 4 μL CleanCap EGFP mRNA (TriLink Biotechnologies) was delivered without
any gRNA. Untransfected hepatocytes were used as a negative control. For each reaction, 1.2
x 106 cells were suspended in 100 μL Primary Mouse/Rat Nucleofection solution (Lonza).
Cells were electroporated using a Nucleofector 2b Device (Lonza) and placed on ice for 15
minutes. Following incubation, 500 μL media consisting of high glucose DMEM +
GlutaMAX (Corning) supplemented with 10% FBS, 1X Penicillin-Streptomycin and 10 mM
HEPES was added to the nucleocuvette vessels. The cell suspension for each reaction was
split between 2 wells in a 6 well collagen coated plate. 24 hours after electroporation, a 0.25
mg/mL Corning Matrigel overlay was added to cells that were kept for genomic DNA
extraction. Each day cells were washed with 1.5 mL 1X PBS and media was replaced.
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4.7 Quantifying Delivery Efficiency
16-24 hours after electroporation, delivery efficiency was quantified by imaging the
GFP cells on an Evos FL (ThermoFisher) or BZ-X810 Fluorescent microscope (Keyence).
For each GFP reaction, GFP and phase contrast images were taken in 3 different areas of the
well. ImageJ (imagej.nih.gov/) was used to count the number of GFP positive cells as well as
the total number of cells, and the GFP percentage was calculated as the ratio of GFP positive
cells to total cells multiplied by 100.
4.8 Genomic DNA Extraction, PCR, and Purification
Three days after electroporation, Hepa 1-6 cells were washed with 50 μL 1X PBS and
removed from wells with 50 μL 0.25% Trypsin EDTA (Fisher Scientific). Suspended cells
were centrifuged for 8 minutes at 2,000 x g. Genomic DNA was extracted using 50 μL
QuickExtract DNA Extraction Solution (Lucigen) according to the manufacturer’s protocol.
For hepatocytes, cells were washed with 1.5 mL 1X PBS and removed from wells with 500
μL 0.25% Trypsin EDTA. Cells were centrifuged at 2000 x g for 10 minutes and genomic
DNA was extracted using 60-80 μL QuickExtract. OneTaq Hot Start DNA Polymerase (New
England Biolabs) was used to perform polymerase chain reaction (PCR) according to the
manufacturer’s instructions for 30 cycles (94˚C for 30 s, 59 or 61˚C for 30 s, 68˚C for 45 s).
Primer annealing temperatures were calculated using New England Biolabs Tm calculator
(tmcalculator.neb.com) and primers are listed in Table 4.8 below:
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Primer Name

Primer Sequence

Melting
Temperature

Annealing
Temperature

Angptl3_FWD

TTCTGCACCTTCAGAGCCAA

65˚C

59˚C

Angptl3_REV

GCAAAGCAAACCCTGAACTGA

64˚C

59˚C

Angptl3-3_FWD

CTCCTCCAAAGCCCTGACCT

68˚C

61˚C

Angptl3-3_REV

GGGAGGGTTACATTCGTGCAAG

66˚C

61˚C

U6sponge-F

GGACTATCATATGTACCGTAACTTGA

63.2˚C

-

Table 4.8: List of primers used for PCR and sequencing.
Cells that were electroporated with Angptl3-1, 3-2, 3-4, and 3-5 were amplified using
the Angptl3 primers, while cells that were transfected with Angptl3-3 were amplified with the
Angptl3-3 primers. PCR products were run on a 1% agarose gel with a negative control to
confirm amplification of genomic DNA. PCR products were then purified with 33-40 μL
Agencourt AMPure XP magnetic beads (Beckman Coulter). DNA concentrations and
A260/280 ratios were measured on the NanoDrop. Samples were sent for Sanger sequencing
(Eurofins Genomics) with 5 μL of the 10 μM forward primer (Angptl3_FWD or Angptl33_FWD) and the volume of sample needed for ≥100 ng of DNA.
4.9 Quantifying Editing Efficiency
To determine the editing efficiency, Tracking of Indels by Decomposition (TIDE,
tide.nki.nl) was used. TIDE is a software that quantifies the editing efficiency and identifies
insertions or deletions (indels) for genome editing tools using Sanger sequences (Brinkman et
al., 2014). After uploading the control (untransfected cells) and edited Sanger sequences, the
sgRNA is entered and aligned to the control sequence to identify the estimated cut site for
Cas9 (Brinkman et al., 2014) The control sequence and experimental sequence are aligned
upstream of the break site, and aberrant sequences are measured downstream from the break
site as a region of decomposition, which can be adjusted (Brinkman et al., 2014). A Pearson
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correlation coefficient (r) is also reported with the editing efficiency results where a higher R2
value correlates to a more confident estimate. The alignment window was adjusted from the
default setting of 100 base pairs to 50 base pairs and the region of decomposition was
adjusted to remove low quality scores at the beginning and end of sequence reads.
Samples were also analyzed with the Synthego software Inference of CRISPR Edits
(ICE; ice.synthego.com). This software is like TIDE and uses Sanger sequencing data to
analyze editing efficiency but does not require the user to manually change any parameters
(Hsiau et al., 2018). Control and edited Sanger sequence files were uploaded along with the
gRNA sequence. The editing efficiency is given as an indel percentage and compares the
edited genomic sequences to wild type unedited sequences (Hsiau et al., 2018). Synthego also
provides a knockout score, which is a measure of the number of cells that have frameshift or
≥21 bp indels. This score is useful for determining if indels in edited sequences will
functionally knockout a targeted gene (Hsiau et al., 2018).
4.10 Plasmid Injection into Mice
Six-week-old male B6. 129S7-Ldlrtm1Her/J mice (The Jackson Laboratory) were
injected with Angptl3-1 CRISPR-Cas9 encoding plasmid DNA. After weighing mice, the
appropriate volume of saline was added to 40 μg plasmid DNA to make a final solution that
was 10% of the mouse weight by volume. The solution was delivered via hydrodynamic tail
vein injection into five mice, and five mice were used as controls that did not receive an
injection. Initial mouse weights and injection volumes are listed below in Table 4.10:
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Mouse

Condition

Initial Weight (g)

Injection Volume (mL)

1

Treated

18.3

1.8 mL

2

Treated

20.0

2.0 mL

3

Treated

20.8

2.0 mL

4

Treated

21.8

2.1 mL

5

Treated

19.9

2.0 mL

6

Control

18.0

-

7

Control

17.5

-

8

Control

17.9

-

9

Control

18.7

-

10

Control

19.5

-

Table 4.10: Initial weights and injection volumes for Angptl3-CRISPR treated mice.
4.11 Lipid Analysis
4.11.1 Serum Collection
To collect serum, 100 μL blood was collected through the cheek into uncoated
microcentrifuge tubes. Blood was allowed to clot at room temperature for 25 minutes, then
centrifuged at 3,000 x g for 10 minutes. Supernatant was collected into new tubes, and 25 μL
of serum was sent for analysis. Blood was collected two weeks after plasmid injection.
4.11.2 Serum Analysis
Serum analysis was used to measure levels of triglycerides (TG) and Angptl3
(courtesy of Dr. Olga Savinova, New York Institute of Technology). Analysis was conducted
according to the manufacturer’s protocol using the following kits: Triglycerides Liquid
Reagent Kit (Pointe Scientific), General Chemistry Controls Level I and II (Pointe Scientific),
and Mouse Angiopoietin-like 3 Quantikine ELISA Kit (R&D Systems).
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4.12 Statistical Analysis
Serum values for TG and Angptl3 levels for CRISPR-injected and control mice were
graphed in GraphPad Prism. An unpaired two-tail T-test was used to compare levels between
the control and experimental groups.
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CHAPTER FIVE
RESULTS
5.1 Guide RNA Designs and Estimated Off-Target Sites
The gRNA designs from Benchling with the five highest on-target scores are shown
below in Table 5.1.1. Angptl3-1 had the highest on-target score, a measure of on-target
activity for the gRNA where scores above 60 are preferred (Doench et al., 2016). Angptl3-2
had the highest off-target score, indicating that this gRNA was predicted to have the lowest
number of sequences that could be potential off-target editing sites.

Sequence

On-Target

Off-Target

Position

Strand

Name

Sequence

PAM

Score

Score

99031333

1

Angptl3-1

TACACTACAAGTTAAAAACG

AGG

75.32487837

66.8023345

99031336

1

Angptl3-2

ACTACAAGTTAAAAACGAGG

AGG

70.68456019

75.958588

99031157

-1

Angptl3-3

GTCCATGACCCAGCTGCAGG

AGG

64.81234792

51.0979099

99031411

1

Angptl3-4

GAAGACAGCCCTTCAACACA

AGG

64.46374046

56.3956156

99031417

1

Angptl3-5

AGCCCTTCAACACAAGGTCA

GGG

64.2856398

56.7499205

Table 5.1.1: Guide RNA designs targeting Angptl3.
The in-silico tool COSMID was used to find predicted off-target sites for each gRNA
design. The number of off-target sites for each design after removing duplicate sites and
ranking sites based on priority are shown in Table 5.1.2. Angptl3-1 had the highest number of
estimated off-target sites, while Angptl3-2 had the least. Comparing the number of predicted
off-target sites from COSMID to the off-target scores provided by Benchling did produce
interesting results, since Angptl3-1 had the second best off-target score.
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Sequence
Name
Angptl3-1
Angptl3-2
Angptl3-3
Angptl3-4
Angptl3-5

sgRNA Sequence
TACACTACAAGTTAAAAACG
ACTACAAGTTAAAAACGAGG
GTCCATGACCCAGCTGCAGG
GAAGACAGCCCTTCAACACA
AGCCCTTCAACACAAGGTCA

Query Sequence
NACACTACAAGTTAAAAACGNRG
NCTACAAGTTAAAAACGAGGNRG
NTCCATGACCCAGCTGCAGGNRG
NAAGACAGCCCTTCAACACANRG
NGCCCTTCAACACAAGGTCANRG

Estimated OffTarget Sites
74
21
50
69
32

Table 5.1.2: Estimated number of off-target sites after ranking.
5.2 Delivery Efficiencies
Phase Contrast and GFP images were taken of cells transfected with GFP, called
“mock transfected cells”, 16-24 hours after electroporation. For each electroporation, images
were taken in three different spots of the 96-well plate that the mock transfected cells were in.
Figure 5.2.1 represents an example of the separate GFP and phase contrast images for Hepa
1-6 cells, where the scale bar is equal to 400 microns; the GFP overlay image can be seen in
Figure 5.2.2. ImageJ was used to count the GFP-positive cells and the total number of cells
present in the phase contrast picture, and the delivery efficiency was taken as a ratio of these
numbers. The ratio for each of the three images was averaged to quantify the mean delivery
efficiency for each electroporation, which is shown graphically in Figure 5.2.3. There was
high variability in the delivery efficiencies, with a range between 26-76%. The GFP overlay
image for primary mouse hepatocytes that were transfected with eGFP mRNA can be seen in
Figure 5.2.4 with a delivery efficiency of 23.1%.
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Figure 5.2.1: GFP and phase contrast images in mock transfected Hepa 1-6 cells 16-24 hours
after electroporation.

Figure 5.2.2: GFP overlay in mock transfected Hepa 1-6 cells.
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Figure 5.2.3: Average delivery efficiencies for each electroporation in Hepa 1-6 cells.

Figure 5.2.4: GFP overlay and average delivery efficiency for electroporation in primary
mouse hepatocytes.
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5.3 Editing Efficiencies
5.3.1 Hepa 1-6 Cells
Plasmid DNA encoding the five different Angptl3-targeting gRNAs and Cas9 were
electroporated into mouse Hepa 1-6 cells to validate the CRISPR designs. Genomic DNA was
extracted and sent for Sanger sequencing, and the editing efficiencies for each design were
quantified with TIDE and Synthego ICE (Figure 5.3.1). Angptl3-1 had the highest editing
efficiency of all five designs, with a mean editing efficiency of 27.15% from TIDE and 28%
from Synthego ICE. Angptl3-2 had the lowest editing efficiency of the five designs, with an
editing efficiency of only 4% from TIDE and <1% from Synthego. These results were
interesting given the high on-target score for this design from COSMID. Angptl3-3 and 3-4
had a range of 9-12% editing efficiency while Angpptl 3-5 ranged from 2-5%. Cells that were
transfected with GFP are listed as “Mock” and had <0.6% editing efficiency. The Synthego
knockout score for each design can be seen in Figure 5.3.2 and is an estimate of the
proportion of edited cells with indels that would result in functional knockout of a gene
(Hsiau et al., 2018). These scores were consistent with the editing efficiencies from Synthego.
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Figure 5.3.1: Mean editing efficiencies from TIDE and Synthego ICE in Hepa 1-6 cells.

Figure 5.3.2: Synthego knockout scores for Angptl3-targeting gRNAs.
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5.3.2 Primary Mouse Hepatocytes
The Angptl3-1 design had the highest editing efficiencies in Hepa 1-6 cells and was
selected for use in further experiments. Angptl3-1 gRNA was delivered with Cas9 mRNA or
Cas9 RNP into primary mouse hepatocytes to compare editing efficiencies with different
forms of Cas9. The editing efficiency for the different Angptl3-1gRNA-Cas9 complexes were
quantified using TIDE and ICE and are shown in Figure 5.3.3 below. Both delivery systems
had high levels of editing, with the Cas9 mRNA system having an editing efficiency of 94%
(TIDE) and 96% (Synthego), and the Cas9 RNP system demonstrating 86% (TIDE) and 93%
(Synthego) editing efficiency. The Synthego knockout scores are also shown below in Figure
5.3.4; Cas9 mRNA had a score of 96 and RNP had a score of 91. No editing was observed in
Mock transfected cells.
Angptl3-1 Editing Efficiency in Mouse Hepatocytes
100
90

Editing Efficiency (%)

80
70
60

50
40
30
20
10
0
mRNA

RNP
TIDE Indels

Mock

Synthego Indels

Figure 5.3.3: TIDE and Synthego editing efficiencies in primary mouse hepatocytes.
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Figure 5.3.4: Synthego knockout scores for Angptl3-1 in primary mouse hepatocytes.
5.4 Serum Analysis
Two weeks after injection, serum was collected from experimental and control groups
and triglyceride and Angptl3 levels were measured. An unpaired T-test with a P value of 0.05
was used to determine any significant differences between the two groups. The CRISPRtreated mice had a lower average serum concentration of Angptl3 than the control mice,
however the difference was not statistically significant (Figure 5.4). The difference in mean
TG levels between the two groups was determined to be statistically significant, with a P
value of 0.0236. A simple linear regression model was used to evaluate the correlation
between Angptl3 and TG, showing a weak positive correlation between the two (Figure 5.4).
Since loss-of-function in ANGPTL3 is associated with lower levels of triglycerides, these
results also indicate that our CRISPR was moderately successful in knocking down Angptl3.
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Figure 5.4: Mean serum levels of Angptl3 and triglycerides for control and CRISPR-treated
mice.
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CHAPTER SIX
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Discussion
In this project, we used in-silico tools to design five different gRNAs targeting
Angptl3 and predicted the number of off-target sites associated with each design. Guide RNAs
must be evaluated for both on- and off-target activity to maximize editing efficiency and try to
minimize off-target editing that remains a concern with Cas9. To verify that our designs
worked, we delivered plasmid DNA encoding the different gRNAs and Cas9 into the liverderived mouse Hepa 1-6 cell line via electroporation. The mean editing efficiency was
quantified for each design with two widely used tools, TIDE, and Synthego ICE. We also
quantified our delivery efficiency with the presence of GFP-positive cells. All five designs
showed some level of editing activity, with Angptl3-1 having the highest editing efficiency of
~28% in Hepa 1-6 cells.
Next, we quantified the editing efficiency of Angptl3-1 in primary mouse hepatocytes
that express Angptl3 in much higher levels than Hepa 1-6 cells. We also evaluated the effects
of using different forms of Cas9, delivering Angptl3-1 sgRNA with Cas9 mRNA or Cas9
RNP. Our results demonstrated very high levels of activity for both designs, with an editing
efficiency of ~95% with Cas9 mRNA and ~90% with Cas9 RNP. These results validate the
high editing activity of our design and indicate that it could be an effective inhibitor of
Angptl3.
Finally, we delivered plasmid DNA encoding the Angptl3-1 gRNA and Cas9 into Ldlr
knockout mice and measured the effects of our CRISPR design on serum levels of Angptl3
and triglycerides. We showed a small reduction in serum Angptl3 levels in the CRISPR-
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treated mice compared to controls, and a statistically significant reduction in triglyceride
levels between the two groups.
6.2 Future Directions
This project provided preliminary results that verified our gRNA designs targeting
Angptl3 and showed acceptable levels of gene editing in both Hepa 1-6 cells and primary
mouse hepatocytes. Future work should repeat delivery of the CRISPR as mRNA and RNP
into primary mouse hepatocytes to achieve statistically significant gene editing results with at
least three biological replicates. While Angptl3-1 had the highest levels of editing, it also had
the highest number of predicted off-target sites according to COSMID. Off-target editing
remains one of the primary safety concerns associated with CRISPR-Cas9 gene editing, and
off-target analysis should be performed in the future to assess whether this gRNA would be
acceptable for further use. Hydrodynamic tail vein injection of plasmid DNA is a relatively
simple and reliable method to effectively deliver gene editing components to the liver;
however, an important next step would be to quantifying editing efficiency through the
extraction of genomic DNA from liver tissue. Future work should focus on this to optimize
our CRISPR delivery method and ensure that we are achieving high levels of editing in
animal models.
A wide variety of gene editing methods including viral and nonviral vectors are being
studied and have shown promising results for the treatment of FH. In addition to knockout of
ANGPTL3, researchers have also started using AAVs to deliver CRISPR designs that
facilitate in vivo correction of Ldlr in mice. Zhao et al. demonstrated correction of a point
mutation in the Ldlr gene that partially restored Ldlr expression (2020). In vivo editing has
been widely adopted in clinical trials but remains limited by safety concerns associated with
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viral vectors and preexisting AAV immunity that could hamper therapeutic benefits. Ex vivo
editing can overcome some of the safety concerns associated with gene editing, and the APAP
selection method developed by Vonada et al. has provided a successful way to select for
edited cells for the correction of liver-based diseases. These principles could be utilized to
develop a novel multiplex ex vivo gene editing approach for FH that couples silencing of
ANGPTL3 through our Angptl3-1 CRISPR design with the knockdown of CYPOR to enhance
for edited cells.
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